Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Elisabeth Mbemba"'
Autor:
Loula Papageorgiou, Kutaiba Alhaj Hussen, Sandrine Thouroude, Elisabeth Mbemba, Héléne Cost, Laurent Garderet, Ismail Elalamy, Annette Larsen, Patrick Van Dreden, Meletios A. Dimopoulos, Mohamad Mohty, Grigoris T. Gerotziafas
Publikováno v:
TH Open, Vol 03, Iss 04, Pp e340-e347 (2019)
Introduction Hypercoagulability is a common blood alteration in newly diagnosed chemotherapy naïve patients with multiple myeloma. The identification of the procoagulant potential of cancer cells, which is principally related to tissue factor (TF) e
Externí odkaz:
https://doaj.org/article/85b41f2b242846199341e7ef5726cf71
Autor:
Elisabeth Mbemba, Chi Mai Tran Huong, Noemie Mourot, Mohammed Baghdadi, Ismail Elalamy, Patrick Van Dreden, Grigoris Gerotziafas
Publikováno v:
Blood. 140:11284-11285
Autor:
Kutaiba Alhaj Hussen, Loula Papageorgiou, Annette K. Larsen, Patrick Van Dreden, Elisabeth Mbemba, Laurent Garderet, Grigoris T. Gerotziafas, Héléne Cost, Meletios A. Dimopoulos, Ismail Elalamy, S. Thouroude, Mohamad Mohty
Publikováno v:
TH Open, Vol 03, Iss 04, Pp e340-e347 (2019)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Introduction Hypercoagulability is a common blood alteration in newly diagnosed chemotherapy naïve patients with multiple myeloma. The identification of the procoagulant potential of cancer cells, which is principally related to tissue factor (TF) e
Publikováno v:
65th Annual Meeting of the Society of Thrombosis and Haemostasis Research.
Autor:
Elisabeth Mbemba, Patrick Van Dreden, Rania Amrane, Huong Chi Mai Tran, Jawed Fareed, Grigorios T. Gerotziafas, Michèle Sabbah, Ismail Elalamy
Publikováno v:
Blood. 138:2136-2136
Background Cancer patients with venous thromboembolism (VTE) or at risk of VTE are treated with antithrombotic agents. Cancer cells express procoagulant properties and induce hypercoagulability in the microenvironment, that could impact the efficienc
Autor:
Annette K. Larsen, Fatoumata Sidibe, Anastasia Spanoudaki, Jérôme Larghero, Jean Pierre Lotz, Patrick Van Dreden, Valérie Vanneaux, Grigoris T. Gerotziafas, Ismail Elalamy, Elisabeth Mbemba
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 24:684-690
The beneficial effect of autologous peripheral blood stem cell transplantation (APBSCT) may be compromised by acute vascular complications related to hypercoagulability. We studied the impact of graft product on thrombin generation of normal plasma a
Autor:
Grigoris T. Gerotziafas, Patrick Van Dreden, Annette K. Larsen, Elisabeth Mbemba, Ismail Elalamy, Aurélie Rousseau
Publikováno v:
Thrombosis Research. 136:1273-1279
Introduction Cancer cells may alter the efficiency of the antithrombotic agents. To explore this possibility, the present study compared the capacity of the LMWH enoxaparin and the specific inhibitors of Xa (apixaban and fondaparinux) to inhibit thro
Autor:
Patrick Van Dreden, Amir Khartechi, Jawed Fareed, Elisabeth Mbemba, Aurèlie Rouseau, Ismail Elalamy, Janine Walenga, Grigoris T. Gerotziafas
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 21:697-704
Background: The patent protection of low-molecular-weight heparins (LMWHs) expired, so the definition of criteria for the biological similarity between LMWH copies and the original product is a real need. Aim: The present in vitro study compared copi
Autor:
Patrick Van Dreden, Jean François Bernaudin, Elisabeth Mbemba, Mouna Sassi, Max Japcowitz, Grigoris T. Gerotziafas, Jawed Fareed, Mohamed Hatmi, Jean Pierre Lotz, Amir Khaterchi, Vassiliki Galea, Marie-Paule Roman, Ismail Elalamy
Publikováno v:
Current Vascular Pharmacology. 12:893-902
Low molecular weight heparins (LMWHs) and fondaparinux are widely used for prophylaxis and treatment of venous thromboembolic disease in cancer patients. However, the optimization of the antithrombotic treatment especially in patients with adenocarci
Autor:
Taher Chakroun, Annette K. Larsen, Mouna Sassi, Patrick Van Dreden, Elisabeth Mbemba, Ismail Elalamy, Grigoris T. Gerotziafas
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 23(2)
Background: A documented relationship between ovarian cancer and thrombosis does exist. Low-molecular-weight heparins (LMWHs) are cornerstone drugs in the primary prevention and treatment of venous thromboembolic events in patients with cancer. Howev